July 3, 2024- The annual number of medtech acquisitions is on course to slump to its lowest level since 2017, according to Needham analysts. Deal volumes are down but values are up, and analysts see the potential for increased activity, citing stabilizing interest rates and low valuations. But they identified antitrust concerns as a barrier that could persist until at least the … [Read more...]
Cleveland Clinic, Masimo partner around RPM and TeleCritical Care
July 3, 2024- Cleveland Clinic and Masimo are partnering to enhance hospital-based remote patient monitoring (RPM), including TeleCritical Care. This includes the integration of Cleveland Clinic’s critical care (eHospital) and non-critical care (eCMU) central patient monitoring platforms with the Masimo Hospital Automation™ platform. The goal is to provide tools for clinicians … [Read more...]
Cedars-Sinai names next president, CEO
July 3, 2024- Cedars-Sinai has named Peter L. Slavin, MD, as the next president and CEO of Cedars-Sinai Medical Center and president and CEO of Cedars-Sinai Health System, effective Oct. 1. Slavin succeeds Thomas M. Priselac, who is retiring after 30 years as president and CEO and 45 years of total service to Cedars-Sinai. Slavin served as president of Massachusetts … [Read more...]
Amazon Clinic is now Amazon One Medical Pay-Per-Visit telehealth service
July 2, 2024- Amazon is folding its telehealth marketplace into primary care chain One Medical. This unifies its healthcare delivery services under one brand as it rebrands its telehealth marketplace, previously Amazon Clinic, to Amazon One Medical Pay-Per-Visit. Amazon Clinic launched in 2022 and it was taken nationwide the next year. Customers now have two options when … [Read more...]
Chevron deference ruling could affect federal healthcare agencies
July 2, 2024- The U.S. Supreme Court’s ruling overturning the Chevron deference and stripping power from federal agencies to interpret and enforce regulations may put a closer microscope on federal healthcare agencies. Under the 40-year legal precedent, courts are required to determine whether an agency’s interpretation of an ambiguous law is reasonable, which has given … [Read more...]
Thermo Fisher Scientific introduces biobased solutions for climate impact in manufacturing of therapies
July 2, 2024- Thermo Fisher Scientific Inc. is contributing to the sustainability of biologics therapy manufacturing by leveraging plant-based materials, rather than fossil fuel materials, to deliver lower-carbon, biobased films for its single-use technology bioprocessing containers (BPCs). The biobased films build on Thermo Fisher’s existing Aegis™ and CX film offerings that … [Read more...]
Roche expands access to cervical cancer screening tools
July 2, 2024- Roche announced that the World Health Organization (WHO) has awarded the cobas® HPV test prequalification designations for use on the cobas® 5800 system and for self-collected samples on the cobas® 5800, 6800 and 8800 systems. These new prequalification designations come just one month after the FDA approved Roche’s HPV self-collection solution and less than a … [Read more...]
Cleveland Clinic launches wellness and diet coaching app featuring food and fitness tracking, support and education
July 1, 2024- Cleveland Clinic and app developer FitNow, Inc. have launched the Cleveland Clinic Diet app, which offers health and diet advice built upon evidence-based nutrition science and clinical success, paired with a comprehensive food and fitness tracker. The app provides individualized guided support with the input of Cleveland Clinic health experts to help users make … [Read more...]
CDC issues updated RSV vaccine guidance for seniors
July 1, 2024- The Centers for Disease Control and Prevention (CDC) have updated its RSV vaccine guidance for seniors this upcoming respiratory season to make it easier for physicians and patients to make treatment and prevention decisions. The CDC is recommending that everyone ages 75 and older receive the RSV vaccine. The CDC also urges people ages 60–74 who are at increased … [Read more...]
Cepheid receives FDA Authorization with CLIA Waiver for Xpert® HCV
July 1, 2024- Cepheid announced that it has received FDA De Novo marketing authorization and Clinical Laboratory Improvement Amendments (CLIA) Waiver approval for Xpert® HCV, the only molecular test in the US to detect hepatitis C virus RNA directly from a human capillary whole blood (fingerstick) sample. The Xpert HCV test is performed on the GeneXpert Xpress System. In the … [Read more...]